Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Advances being used to treat cancer are now being applied to lupus, rheumatoid arthritis, and other disorders.

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

The FDA approved use of the Atalante X robotic exoskeleton, which allows people with mobility issues to stand upright, for MS ...

WASHINGTON (AP) -- The Food and Drug Administration approved Sanofi's multiple sclerosis drug Aubagio late Wednesday for adults experiencing flare-ups of the neurological disorder. The once-a-day pill ...